Fusion Pharmaceuticals Dirección
Dirección controles de criterios 4/4
El CEO de Fusion Pharmaceuticals es John Valliant , nombrado en Dec 2014, tiene una permanencia de 9.5 años. compensación anual total es $2.08M, compuesta por 28.7% salario y 71.3% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.37% de las acciones de la empresa, por valor de $6.86M. La antigüedad media del equipo directivo y de la junta directiva es de 2.8 años y 5.2 años, respectivamente.
Información clave
John Valliant
Chief Executive Officer (CEO)
US$2.1m
Compensación total
| Porcentaje del salario del CEO | 28.7% |
| Permanencia del CEO | 9.5yrs |
| Participación del CEO | 0.4% |
| Permanencia media de la dirección | 2.8yrs |
| Promedio de permanencia en la Junta Directiva | 5.2yrs |
Actualizaciones recientes de la dirección
Recent updates
Fusion Pharmaceuticals' Partnerships Strengthen Long-Term Outlook
Mar 03Health Check: How Prudently Does Fusion Pharmaceuticals (NASDAQ:FUSN) Use Debt?
Jan 30
Fusion Pharmaceuticals initiated at buy at Truist on lead candidate for solid tumors
Sep 16Fusion Pharma doses first patient in phase 1/2 study for solid tumors treatment
Aug 29Will Fusion Pharmaceuticals (NASDAQ:FUSN) Spend Its Cash Wisely?
Aug 10Fusion Pharmaceuticals GAAP EPS of -$0.44 beats by $0.09, revenue of $0.57M beats by $0.46M
Aug 09Fusion Pharma wins FDA nod to start trials for solid tumor candidate
Jun 23We're Not Very Worried About Fusion Pharmaceuticals' (NASDAQ:FUSN) Cash Burn Rate
Jan 16We're Not Very Worried About Fusion Pharmaceuticals' (NASDAQ:FUSN) Cash Burn Rate
Aug 28Fusion Pharma trades higher on early-stage data for cancer therapy
Jun 14We're Hopeful That Fusion Pharmaceuticals (NASDAQ:FUSN) Will Use Its Cash Wisely
Apr 05How Much Of Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) Do Institutions Own?
Mar 01Who Has Been Buying Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) Shares?
Jan 25Here's Why We're Not Too Worried About Fusion Pharmaceuticals' (NASDAQ:FUSN) Cash Burn Situation
Dec 21Fusion Pharmaceuticals EPS misses by $0.04
Nov 10Fusion Pharma teams up with AstraZeneca in next-gen radiopharmaceuticals for cancer
Nov 02Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -US$104m |
| Dec 31 2023 | US$2m | US$597k | -US$95m |
| Sep 30 2023 | n/a | n/a | -US$91m |
| Jun 30 2023 | n/a | n/a | -US$98m |
| Mar 31 2023 | n/a | n/a | -US$92m |
| Dec 31 2022 | US$3m | US$595k | -US$88m |
| Sep 30 2022 | n/a | n/a | -US$80m |
| Jun 30 2022 | n/a | n/a | -US$76m |
| Mar 31 2022 | n/a | n/a | -US$83m |
| Dec 31 2021 | US$3m | US$597k | -US$81m |
| Sep 30 2021 | n/a | n/a | -US$77m |
| Jun 30 2021 | n/a | n/a | -US$68m |
| Mar 31 2021 | n/a | n/a | -US$86m |
| Dec 31 2020 | US$7m | US$505k | -US$80m |
| Sep 30 2020 | n/a | n/a | -US$75m |
| Jun 30 2020 | n/a | n/a | -US$65m |
| Mar 31 2020 | n/a | n/a | -US$24m |
| Dec 31 2019 | US$1m | US$399k | -US$16m |
Compensación vs. Mercado: La compensación total de John($USD2.08M) está por debajo de la media de empresas de tamaño similar en el mercado US ($USD5.57M).
Compensación vs. Ingresos: La compensación de John ha sido consistente con los resultados de la empresa en el último año.
CEO
John Valliant (53 yo)
9.5yrs
Permanencia
US$2,081,586
Compensación
Dr. John F. Valliant Ph D, is Founder of Fusion Pharmaceuticals Inc. and its Chief Executive Officer & Director since December 2014. He served as Member of Scientific Advisory Board of Molecular Insight Ph...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Founder | 9.5yrs | US$2.08m | 0.37% $ 6.9m | |
| President & Chief Business Officer | 2.8yrs | US$1.41m | 0.015% $ 276.8k | |
| CFO & Compliance Officer | 5.3yrs | US$1.30m | 0.012% $ 224.4k | |
| Chief Technology Officer | 2.6yrs | US$1.42m | 0.045% $ 829.5k | |
| Chief Scientific Officer | 2.6yrs | sin datos | 0.014% $ 257.7k | |
| Senior Director of Investor Relations & Corporate Communications | no data | sin datos | sin datos | |
| Chief Legal Officer | 3.8yrs | sin datos | sin datos | |
| Senior Vice President of Business Development | 2.8yrs | sin datos | sin datos | |
| Chief of Staff | no data | sin datos | sin datos | |
| Executive Vice President of Medical Director & Clinical Development | 2.2yrs | sin datos | sin datos | |
| Chief Medical Officer | 1.6yrs | sin datos | sin datos |
2.8yrs
Permanencia media
53.5yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de FUSN se considera experimentado (2.8 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Founder | 9.5yrs | US$2.08m | 0.37% $ 6.9m | |
| Independent Chairperson of the Board | 3.7yrs | US$126.49k | 0% $ 0 | |
| Independent Director | 4.5yrs | US$103.49k | 0% $ 0 | |
| Independent Director | 4.4yrs | US$108.24k | 0.066% $ 1.2m | |
| Independent Director | less than a year | US$101.89k | 0% $ 0 | |
| Member of Advisory Board | 5.9yrs | sin datos | sin datos | |
| Independent Director | 3.2yrs | US$98.49k | 0% $ 0 | |
| Member of Advisory Board | 5.9yrs | sin datos | sin datos | |
| Member of Advisory Board | 5.9yrs | sin datos | sin datos | |
| Member of Advisory Board | 5.9yrs | sin datos | sin datos | |
| Member of Advisory Board | 5.9yrs | sin datos | sin datos | |
| Independent Director | 3.3yrs | US$97.49k | 0% $ 0 |
5.2yrs
Permanencia media
53yo
Promedio de edad
Junta con experiencia: La junta directiva de FUSN se considera experimentada (5.2 años de antigüedad promedio).